|
1
|
Massagué J: TGF-β signaling in development
and disease. FEBS Lett. 586:18332012. View Article : Google Scholar
|
|
2
|
Hata A and Chen YG: TGF-beta signaling
from receptors to smads. Cold Spring Harb Perspect Biol.
8:a0220612016. View Article : Google Scholar
|
|
3
|
Zhang Y, Alexander PB and Wang XF:
TGF-beta family signaling in the control of cell proliferation and
survival. Cold Spring Harb Perspect Biol. 9:a0221452017. View Article : Google Scholar
|
|
4
|
Wu MY and Hill CS: Tgf-beta superfamily
signaling in embryonic development and homeostasis. Dev Cell.
16:329–343. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ma W, Qin Y, Chapuy B and Lu C: LRRC33 is
a novel binding and potential regulating protein of TGF-β1 function
in human acute myeloid leukemia cells. PLoS One. 14:e02134822019.
View Article : Google Scholar
|
|
6
|
Maishi N and Hida K: Tumor endothelial
cells accelerate tumor metastasis. Cancer Sci. 108:1921–1926. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Selleri S, Rumio C, Sabatino M, Marincola
FM and Wang E: Tumor microenvironment and the immune response. Surg
Oncol Clin N Am. 16:737–753. vii–viii. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yamamoto T, Akisue T, Marui T, Fujita I,
Matsumoto K, Hitora T, Kawamoto T, Nagira K, Nakatani T and
Kurosaka M: Expression of transforming growth factor beta isoforms
and their receptors in malignant fibrous histiocytoma of soft
tissues. Clin Cancer Res. 10:5804–5807. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dropmann A, Dediulia T, Breitkopf-Heinlein
K, Korhonen H, Janicot M, Weber SN, Thomas M, Piiper A, Bertran E,
Fabregat I, et al: TGF-β1 and TGF-β2 abundance in liver diseases of
mice and men. Oncotarget. 7:19499–19518. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ebert MP, Yu J, Miehlke S, Fei G,
Lendeckel U, Ridwelski K, Stolte M, Bayerdörffer E and
Malfertheiner P: Expression of transforming growth factor beta-1 in
gastric cancer and in the gastric mucosa of first-degree relatives
of patients with gastric cancer. Br J Cancer. 82:1795–1800. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Andersson J, Tran DQ, Pesu M, Davidson TS,
Ramsey H, O'Shea JJ and Shevach EM: CD4+
FoxP3+ regulatory T cells confer infectious tolerance in
a TGF-beta-dependent manner. J Exp Med. 205:1975–1981. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Peng L, Yuan XQ, Zhang CY, Ye F, Zhou HF,
Li WL, Liu ZY, Zhang YQ, Pan X and Li GC: High TGF-beta1 expression
predicts poor disease prognosis in hepatocellular carcinoma
patients. Oncotarget. 8:34387–34397. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Neuzillet C, de Gramont A,
Tijeras-Raballand A, de Mestier L, Cros J, Faivre S and Raymond E:
Perspectives of TGF-β inhibition in pancreatic and hepatocellular
carcinomas. Oncotarget. 5:78–94. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Papageorgis P: TGFbeta signaling in tumor
initiation, epithelial-to-mesenchymal transition, and metastasis. J
Oncol. 2015:5871932015. View Article : Google Scholar
|
|
15
|
Vander Ark A, Cao J and Li X: TGF-β
receptors: In and beyond TGF-β signaling. Cell Signal. 52:112–120.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Baxter SW, Choong DY, Eccles DM and
Campbell IG: Transforming growth factor beta receptor 1 polyalanine
polymorphism and exon 5 mutation analysis in breast and ovarian
cancer. Cancer Epidemiol Biomarkers Prev. 11:211–214.
2002.PubMed/NCBI
|
|
17
|
Liu J, Johnson K, Li J, Piamonte V, Steffy
BM, Hsieh MH, Ng N, Zhang J, Walker JR, Ding S, et al: Regenerative
phenotype in mice with a point mutation in transforming growth
factor beta type I receptor (TGFBR1). Proc Natl Acad Sci USA.
108:14560–14565. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang F, Yu Q, Chu Y, Zhu X, Lu W, Liu Q
and Wang Q: MicroRNA-98-5p inhibits proliferation and metastasis in
non-small cell lung cancer by targeting TGFBR1. Int J Oncol.
54:128–138. 2019.
|
|
19
|
Grandclement C, Pallandre JR, Valmary
Degano S, Viel E, Bouard A, Balland J, Rémy-Martin JP, Simon B,
Rouleau A, Boireau W, et al: Neuropilin-2 expression promotes
TGF-β1-mediated epithelial to mesenchymal transition in colorectal
cancer cells. PLoS One. 6:e204442011. View Article : Google Scholar
|
|
20
|
He B, Xu T, Pan B, Pan Y, Wang X, Dong J,
Sun H, Xu X, Liu X and Wang S: Polymorphisms of TGFBR1, TLR4 are
associated with prognosis of gastric cancer in a Chinese
population. Cancer Cell Int. 18:1912018. View Article : Google Scholar :
|
|
21
|
Kim W, Kim E, Lee S, Kim D, Chun J, Park
KH, Youn H and Youn B: TFAP2C-mediated upregulation of TGFBR1
promotes lung tumorigenesis and epithelial-mesenchymal transition.
Exp Mol Med. 48:e2732016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang L, Song X, Chen X, Wang Q, Zheng X,
Wu C and Jiang J: Circular RNA CircCACTIN promotes gastric cancer
progression by sponging MiR-331-3p and regulating TGFBR1
expression. Int J Biol Sci. 15:1091–1103. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Knight PG and Glister C: TGF-beta
superfamily members and ovarian follicle development. Reproduction.
132:191–206. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hinck AP, Mueller TD and Springer TA:
Structural biology and evolution of the TGF-β family. Cold Spring
Harb Perspect Biol. 8. pp. a0221032016, View Article : Google Scholar
|
|
25
|
Meng XM, Nikolic-Paterson DJ and Lan HY:
TGF-β: The master regulator of fibrosis. Nat Rev Nephrol.
12:325–338. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang T, David L, Mendoza V, Yang Y,
Villarreal M, De K, Sun L, Fang X, López-Casillas F, Wrana JL and
Hinck AP: TGF-β signalling is mediated by two autonomously
functioning TβRI:TβRII pairs. EMBO J. 30:1263–1276. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Feng XH and Derynck R: A kinase subdomain
of transforming growth factor-beta (TGF-beta) type I receptor
determines the TGF-beta intracellular signaling specificity. EMBO
J. 16:3912–3923. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lo RS, Chen YG, Shi Y, Pavletich NP and
Massagué J: The L3 loop: A structural motif determining specific
interactions between SMAD proteins and TGF-beta receptors. EMBO J.
17:996–1005. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Itman C, Mendis S, Barakat B and Loveland
KL: All in the family: TGF-beta family action in testis
development. Reproduction. 132:233–246. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Attisano L and Wrana JL: Signal
transduction by the TGF-beta superfamily. Science. 296:1646–1647.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huynh LK, Hipolito CJ and Ten Dijke P: A
perspective on the development of TGF-beta inhibitors for cancer
treatment. Biomolecules. 9:7432019. View Article : Google Scholar
|
|
32
|
Wu Y, Tran T, Dwabe S, Sarkissyan M, Kim
J, Nava M, Clayton S, Pietras R, Farias-Eisner R and Vadgama JV:
A83-01 inhibits TGF-β-induced upregulation of Wnt3 and epithelial
to mesenchymal transition in HER2-overexpressing breast cancer
cells. Breast Cancer Res Treat. 163:449–460. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Katagiri T and Watabe T: Bone
morphogenetic proteins. Cold Spring Harb Perspect Biol.
8:a0218992016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Katz LH, Li Y, Chen JS, Muñoz NM, Majumdar
A, Chen J and Mishra L: Targeting TGF-β signaling in cancer. Expert
Opin Ther Targets. 17:743–760. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Krenning G, Barauna VG, Krieger JE,
Harmsen MC and Moonen JR: Endothelial plasticity: Shifting
phenotypes through force feedback. Stem Cells Int.
2016:97629592016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shi M, Zhu J, Wang R, Chen X, Mi L, Walz T
and Springer TA: Latent TGF-β structure and activation. Nature.
474:343–349. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang J, Li H, Yi D, Lai C, Wang H, Zou W
and Cao B: Knockdown of vascular cell adhesion molecule 1 impedes
transforming growth factor beta 1-mediated proliferation,
migration, and invasion of endometriotic cyst stromal cells. Reprod
Biol Endocrinol. 17:692019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Robertson IB, Horiguchi M, Zilberberg L,
Dabovic B, Hadjiolova K and Rifkin DB: Latent TGF-β-binding
proteins. Matrix Biol. 47:44–53. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ehrlich M, Horbelt D, Marom B, Knaus P and
Henis YI: Homomeric and heteromeric complexes among TGF-beta and
BMP receptors and their roles in signaling. Cell Signal.
23:1424–1432. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
ten Dijke P, Miyazono K and Heldin CH:
Signaling via hetero-oligomeric complexes of type I and type II
serine/threonine kinase receptors. Curr Opin Cell Biol. 8:139–145.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sun D, Han S, Liu C, Zhou R, Sun W, Zhang
Z and Qu J: Microrna-199a-5p functions as a tumor suppressor via
suppressing connective tissue growth factor (CTGF) in follicular
thyroid carcinoma. Med Sci Monit. 22:1210–1217. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Das R, Xu S, Nguyen TT, Quan X, Choi SK,
Kim SJ, Lee EY, Cha SK and Park KS: Transforming growth factor
β1-induced apoptosis in podocytes via the extracellular
signal-regulated kinase-mammalian target of rapamycin complex
1-NADPH Oxidase 4 axis. J Biol Chem. 290:30830–30842. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mihaly SR, Ninomiya-Tsuji J and Morioka S:
TAK1 control of cell death. Cell Death Differ. 21:1667–1676. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tvrdík D, Dundr P, Povýsil C, Pytlík R and
Planková M: Up-regulation of p21WAF1 expression is mediated by
Sp1/Sp3 transcription factors in TGFbeta1-arrested malignant B
cells. Med Sci Monit. 12:BR227–BR234. 2006.PubMed/NCBI
|
|
45
|
Stanilova S, Stanilov N, Julianov A,
Manolova I and Miteva L: Transforming growth factor-β1 gene
promoter -509C/T polymorphism in association with expression
affects colorectal cancer development and depends on gender. PLoS
One. 13:e02017752018. View Article : Google Scholar
|
|
46
|
Al Shareef Z, Kardooni H, Murillo-Garzó V,
Domenici G, Stylianakis E, Steel JH, Rabano M, Gorroño-Etxebarria
I, Zabalza I, Vivanco MD, et al: Protective effect of stromal
Dickkopf-3 in prostate cancer: Opposing roles for TGFBI and ECM-1.
Oncogene. 37:5305–5324. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang ST, Liu JJ, Wang CZ, Lin B, Hao YY,
Wang YF, Gao S, Qi Y, Zhang SL and Iwamori M: Expression and
correlation of Lewis y antigen and TGF-beta1 in ovarian epithelial
carcinoma. Oncol Rep. 27:1065–1071. 2012. View Article : Google Scholar
|
|
48
|
Zhang N, Bi X, Zeng Y, Zhu Y, Zhang Z, Liu
Y, Wang J, Li X, Bi J and Kong C: TGF-β1 promotes the migration and
invasion of bladder carcinoma cells by increasing fascin1
expression. Oncol Rep. 36:977–983. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wakefield LM, Letterio JJ, Chen T,
Danielpour D, Allison RS, Pai LH, Denicoff AM, Noone MH, Cowan KH,
O'Shaughnessy JA, et al: Transforming growth factor-beta1
circulates in normal human plasma and is unchanged in advanced
metastatic breast cancer. Clin Cancer Res. 1:129–136.
1995.PubMed/NCBI
|
|
50
|
Shuang ZY, Wu WC, Xu J, Lin G, Liu YC, Lao
XM, Zheng L and Li S: Transforming growth factor-β1-induced
epithelial-mesenchymal transition generates ALDH-positive cells
with stem cell properties in cholangiocarcinoma. Cancer Lett.
354:320–328. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Safina A, Vandette E and Bakin AV: ALK5
promotes tumor angiogenesis by upregulating matrix
metalloproteinase-9 in tumor cells. Oncogene. 26:2407–2422. 2007.
View Article : Google Scholar
|
|
52
|
Moore-Smith L and Pasche B: TGFBR1
signaling and breast cancer. J Mammary Gland Biol Neoplasia.
16:89–95. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Rosman DS, Phukan S, Huang CC and Pasche
B: TGFBR1*6A enhances the migration and invasion of MCF-7 breast
cancer cells through RhoA activation. Cancer Res. 68:1319–1328.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Slattery ML, Lundgreen A, Herrick JS,
Wolff RK and Caan BJ: Genetic variation in the transforming growth
factor-β signaling pathway and survival after diagnosis with colon
and rectal cancer. Cancer. 117:4175–4183. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Javle M, Li Y, Tan D, Dong X, Chang P, Kar
S and Li D: Biomarkers of TGF-β signaling pathway and prognosis of
pancreatic cancer. PLoS One. 9:e859422014. View Article : Google Scholar
|
|
56
|
Bian Y, Knobloch TJ, Sadim M, Kaklamani V,
Raji A, Yang GY, Weghorst CM and Pasche B: Somatic acquisition of
TGFBR1*6A by epithelial and stromal cells during head and neck and
colon cancer development. Hum Mol Genet. 16:3128–3135. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Pasche B, Pennison MJ, Jimenez H and Wang
M: TGFBR1 and cancer susceptibility. Trans Am Clin Climatol Assoc.
125:300–312. 2014.PubMed/NCBI
|
|
58
|
Myers ER, Moorman P, Gierisch JM,
Havrilesky LJ, Grimm LJ, Ghate S, Davidson B, Mongtomery RC,
Crowley MJ, McCrory DC, et al: Benefits and harms of breast cancer
screening: A systematic review. JAMA. 314:1615–1634. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Oeffinger KC, Fontham ET, Etzioni R,
Herzig A, Michaelson JS, Shih YC, Walter LC, Church TR, Flowers CR,
LaMonte SJ, et al: Breast cancer screening for women at average
risk: 2015 guide-line update from the American cancer society.
JAMA. 314:1599–1614. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
DeSantis CE, Ma J, Goding Sauer A, Newman
LA and Jemal A: Breast cancer statistics, 2017 racial disparity in
mortality by state. CA Cancer J Clin. 67:439–448. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Park SJ, Kim JG, Kim ND, Yang K, Shim JW
and Heo K: Estradiol, TGF-β1 and hypoxia promote breast cancer
stemness and EMT-mediated breast cancer migration. Oncol Lett.
11:1895–1902. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Menezes ME, Shen XN, Das SK, Emdad L,
Sarkar D and Fisher PB: MDA-9/Syntenin (SDCBP) modulates small
GTPases RhoA and Cdc42 via transforming growth factor β1 to enhance
epithelial-mesenchymal transition in breast cancer. Oncotarget.
7:80175–80189. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wang S, Huang M, Wang Z, Wang W, Zhang Z,
Qu S and Liu C: MicroRNA-133b targets TGFβ receptor I to inhibit
TGF-β-induced epithelial-to-mesenchymal transition and metastasis
by suppressing the TGF-β/SMAD pathway in breast cancer. Int J
Oncol. 55:1097–1109. 2019.PubMed/NCBI
|
|
64
|
Lee YS and Dutta A: MicroRNAs in cancer.
Annu Rev Pathol. 4:199–227. 2009. View Article : Google Scholar :
|
|
65
|
Ye Z, Zhao L, Li J, Chen W and Li X:
MiR-30d blocked transforming growth Factor beta1-induced
epithelial-mesenchymal transition by targeting snail in ovarian
cancer cells. Int J Gynecol Cancer. 25:1574–1581. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Dai X, Fang M, Li S, Yan Y, Zhong Y and Du
B: MiR-21 is involved in transforming growth factor β1-induced
chemoresistance and invasion by targeting PTEN in breast cancer.
Oncol Lett. 14:6929–6936. 2017.PubMed/NCBI
|
|
67
|
Li C, Zhou D, Hong H, Yang S, Zhang L, Li
S, Hu P, Ren H, Mei Z and Tang H: TGFβ1-miR-140-5p axis mediated
up-regulation of Flap Endonuclease 1 promotes
epithelial-mesenchymal transition in hepatocellular carcinoma.
Aging (Albany NY). 11:5593–5612. 2019. View Article : Google Scholar
|
|
68
|
Chen Y, Huang S, Wu B, Fang J, Zhu M, Sun
L, Zhang L, Zhang Y, Sun M, Guo L and Wang S: Transforming growth
factor-β1 promotes breast cancer metastasis by downregulating
miR-196a-3p expression. Oncotarget. 8:49110–49122. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zhao XP, Huang YY, Huang Y, Lei P, Peng
JL, Wu S, Wang M, Li WH, Zhu HF and Shen GX: Transforming growth
factor-beta1 upregulates the expression of CXC chemokine receptor 4
(CXCR4) in human breast cancer MCF-7 cells. Acta Pharmacol Sin.
31:347–354. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Chen HS, Bai MH, Zhang T, Li GD and Liu M:
Ellagic acid induces cell cycle arrest and apoptosis through
TGF-β/Smad3 signaling pathway in human breast cancer MCF-7 cells.
Int J Oncol. 46:1730–1738. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Mishra AK, Parish CR, Wong ML, Licinio J
and Blackburn AC: Leptin signals via TGFB1 to promote metastatic
potential and stemness in breast cancer. PLoS One. 12:e01784542017.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Fallone F, Deudon R, Muller C and Vaysse
C: Breast cancer, obesity and adipose tissue: A high-risk
combination. Med Sci (Paris). 34:1079–1086. 2018.In French.
View Article : Google Scholar
|
|
73
|
Lee K, Kruper L, Dieli-Conwright CM and
Mortimer JE: The impact of obesity on breast cancer diagnosis and
treatment. Curr Oncol Rep. 21:412019. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Catteau X, Simon P and Noël JC:
Myofibroblastic stromal reaction and lymph node status in invasive
breast carcinoma: Possible role of the TGF-β1/TGF-βR1 pathway. BMC
Cancer. 14:4992014. View Article : Google Scholar
|
|
75
|
Cox DG, Penney K, Guo Q, Hankinson SE and
Hunter DJ: TGFB1 and TGFBR1 polymorphisms and breast cancer risk in
the Nurses' Health Study. BMC Cancer. 7:1752007. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Benson AB, Venook AP, Al-Hawary MM,
Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D,
Engstrom PF, et al: NCCN guidelines insights: Colon cancer, version
2. 2018.J Natl Compr Canc Netw. 16:359–369. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Siegel RL, Miller KD, Goding Sauer A,
Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA and Jemal
A: Colorectal cancer statistics, 2020. CA Cancer J Clin.
70:145–164. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Xu Y and Pasche B: TGF-beta signaling
alterations and susceptibility to colorectal cancer. Hum Mol Genet.
16(Spec 1 SPEC): R14–R20. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Kong J, Du J, Wang Y, Yang M, Gao J, Wei
X, Fang W, Zhan J and Zhang H: Focal adhesion molecule Kindlin-1
mediates activation of TGF-β signaling by interacting with TGF-βRI,
SARA and Smad3 in colorectal cancer cells. Oncotarget.
7:76224–76237. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Chen K, Wei H, Ling S and Yi C: Expression
and significance of transforming growth factor-beta1 in epithelial
ovarian cancer and its extracellular matrix. Oncol Lett.
8:2171–2174. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Engle SJ, Hoying JB, Boivin GP, Ormsby I,
Gartside PS and Doetschman T: Transforming growth factor beta1
suppresses nonmetastatic colon cancer at an early stage of
tumorigenesis. Cancer Res. 59:3379–3386. 1999.PubMed/NCBI
|
|
82
|
Schmidt-Weber CB and Blaser K: Regulation
and role of transforming growth factor-beta in immune tolerance
induction and inflammation. Curr Opin Immunol. 16:709–716. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Bierie B and Moses HL: Transforming growth
factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth
Factor Rev. 21:49–59. 2010. View Article : Google Scholar
|
|
84
|
Vrba L and Futscher BW: Epigenetic
silencing of lncRNA MORT in 16 TCGA cancer types. F1000Res.
7:2112018. View Article : Google Scholar :
|
|
85
|
Zhou T, Wu L, Zong Z, Ma N, Li Y, Jiang Z,
Wang Q and Chen S: Long non-coding RNA mortal obligate RNA
transcript inhibits the migration and invasion of colon cancer
cells by inactivating transforming growth factor β1. Oncol Lett.
19:1131–1136. 2020.PubMed/NCBI
|
|
86
|
Townsend PA, Cutress RI, Sharp A, Brimmell
M and Packham G: BAG-1: A multifunctional regulator of cell growth
and survival. Biochim Biophys Acta. 1603:83–98. 2003.PubMed/NCBI
|
|
87
|
Skeen VR, Collard TJ, Southern SL,
Greenhough A, Hague A, Townsend PA, Paraskeva C and Williams AC:
BAG-1 suppresses expression of the key regulatory cytokine
transforming growth factor β (TGF-β1) in colorectal tumour cells.
Oncogene. 32:4490–4499. 2013. View Article : Google Scholar
|
|
88
|
Dumond A, Demange L and Pagès G:
Neuropilins: Relevant therapeutic targets to improve the treatment
of cancers. Med Sci (Paris). 36:487–496. 2020.In French. View Article : Google Scholar
|
|
89
|
Huang Y, Fang W, Wang Y, Yang W and Xiong
B: Transforming growth factor-β1 induces glutathione peroxidase-1
and protects from H2O2-induced cell death in colon cancer cells via
the Smad2/ERK1/2/HIF-1α pathway. Int J Mol Med. 29:906–912.
2012.PubMed/NCBI
|
|
90
|
Lei XG, Cheng WH and McClung JP: Metabolic
regulation and function of glutathione peroxidase-1. Annu Rev Nutr.
27:41–61. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Li Y, Zhu G, Zhai H, Jia J, Yang W, Li X
and Liu L: Simultaneous stimulation with tumor necrosis factor-α
and transforming growth factor-β1 induces epithelial-mesenchymal
transition in colon cancer cells via the NF-κB pathway. Oncol Lett.
15:6873–6880. 2018.PubMed/NCBI
|
|
92
|
Tomsic J, Guda K, Liyanarachchi S, Hampel
H, Natale L, Markowitz SD, Tanner SM and de la Chapelle A:
Allele-specific expression of TGFBR1 in colon cancer patients.
Carcinogenesis. 31:1800–1804. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Zhou R, Huang Y, Cheng B, Wang Y and Xiong
B: TGFBR1*6A is a potential modifier of migration and invasion in
colorectal cancer cells. Oncol Lett. 15:3971–3976. 2018.PubMed/NCBI
|
|
94
|
Luyimbazi D, Nelson RA, Choi AH, Li L,
Chao J, Sun V, Hamner JB and Kim J: Estimates of conditional
survival in gastric cancer reveal a reduction of racial disparities
with long-term follow-up. J Gastrointest Surg. 19:251–257. 2015.
View Article : Google Scholar
|
|
95
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Pennison M and Pasche B: Targeting
transforming growth factor-beta signaling. Curr Opin Oncol.
19:579–585. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Derynck R and Zhang YE: Smad-dependent and
Smad-independent pathways in TGF-beta family signalling. Nature.
425:577–584. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Ijichi H, Ikenoue T, Kato N, Mitsuno Y,
Togo G, Kato J, Kanai F, Shiratori Y and Omata M: Systematic
analysis of the TGF-beta-Smad signaling pathway in gastrointestinal
cancer cells. Biochem Biophys Res Commun. 289:350–357. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Ma GF, Miao Q, Zeng XQ, Luo TC, Ma LL, Liu
YM, Lian JJ, Gao H and Chen SY: Transforming growth factor-β1 and
-β2 in gastric precancer and cancer and roles in tumor-cell
interactions with peripheral blood mononuclear cells in vitro. PLoS
One. 8:e542492013. View Article : Google Scholar
|
|
100
|
Zhou Y, Jin GF, Jiang GJ, Wang HM, Tan YF,
Ding WL, Wang LN, Chen WS, Ke Q, Shen J, et al: Correlations of
polymorphisms of TGFB1 and TGFBR2 genes to genetic susceptibility
to gastric cancer. Ai Zheng. 26:581–585. 2007.In Chinese.
PubMed/NCBI
|
|
101
|
Yanagihara K and Tsumuraya M: Transforming
growth factor beta 1 induces apoptotic cell death in cultured human
gastric carcinoma cells. Cancer Res. 52:4042–4045. 1992.PubMed/NCBI
|
|
102
|
Wang KS, Hu ZL, Li JH, Xiao DS and Wen JF:
Enhancement of metastatic and invasive capacity of gastric cancer
cells by transforming growth factor-beta1. Acta Biochim Biophys Sin
(Shanghai). 38:179–186. 2006. View Article : Google Scholar
|
|
103
|
Takeuchi Y and Nishikawa H: Roles of
regulatory T cells in cancer immunity. Int Immunol. 28:401–409.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Deng B, Zhu JM, Wang Y, Liu TT, Ding YB,
Xiao WM, Lu GT, Bo P and Shen XZ: Intratumor hypoxia promotes
immune tolerance by inducing regulatory T cells via TGF-β1 in
gastric cancer. PLoS One. 8:e637772013. View Article : Google Scholar
|
|
105
|
Lee MS, Kim TY, Kim YB, Lee SY, Ko SG,
Jong HS, Kim TY, Bang YJ and Lee JW: The signaling network of
transforming growth factor beta1, protein kinase Cdelta, and
integrin underlies the spreading and invasiveness of gastric
carcinoma cells. Mol Cell Biol. 25:6921–6936. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Zhou H, Wang K, Hu Z and Wen J: TGF-β1
alters microRNA profile in human gastric cancer cells. Chin J
Cancer Res. 25:102–111. 2013.PubMed/NCBI
|
|
107
|
Zhu Y, Kong F, Zhang C, Ma C, Xia H, Quan
B and Cui H: CD133 mediates the TGF-β1-induced activation of the
PI3K/ERK/P70S6K signaling pathway in gastric cancer cells. Oncol
Lett. 14:7211–7216. 2017.
|
|
108
|
Zhao Y, Xia S, Cao C and Du X: Effect of
TGF-β1 on apoptosis of colon cancer cells via the ERK signaling
pathway. J BUON. 24:449–455. 2019.PubMed/NCBI
|
|
109
|
Jin S, Gao J, Qi Y, Hao Y, Li X, Liu Q,
Liu J, Liu D, Zhu L and Lin B: TGF-β1 fucosylation enhances the
autophagy and mitophagy via PI3K/Akt and Ras-Raf-MEK-ERK in ovarian
carcinoma. Biochem Biophys Res Commun. 524:970–976. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Cascione M, Leporatti S, Dituri F and
Giannelli G: Transforming growth factor-β promotes morphomechanical
effects involved in epithelial to mesenchymal transition in living
hepatocellular carcinoma. Int J Mol Sci. 20:1082018. View Article : Google Scholar
|
|
111
|
Sun SL and Wang XY: TGF-β1 promotes
proliferation and invasion of hepatocellular carcinoma cell line
HepG2 by activating GLI-1 signaling. Eur Rev Med Pharmacol Sci.
22:7688–7695. 2018.PubMed/NCBI
|
|
112
|
Qu Z, Feng J, Pan H, Jiang Y, Duan Y and
Fa Z: Exosomes derived from HCC cells with different invasion
characteristics mediated EMT through TGF-β/Smad signaling pathway.
Onco Targets Ther. 12:6897–6905. 2019. View Article : Google Scholar :
|
|
113
|
Zhang C, Chen B, Jiao A, Li F, Sun N,
Zhang G and Zhang J: MiR-663a inhibits tumor growth and invasion by
regulating TGF-β1 in hepatocellular carcinoma. BMC Cancer.
18:11792018. View Article : Google Scholar
|
|
114
|
Tang YH, He GL, Huang SZ, Zhong KB, Liao
H, Cai L, Gao Y, Peng ZW and Fu SJ: The long noncoding RNA AK002107
negatively modulates miR-140-5p and targets TGFBR1 to induce
epithelial-mesenchymal transition in hepatocellular carcinoma. Mol
Oncol. 13:1296–1310. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Zhang Y, Li B, Li X, Tan H, Cheng D and
Shi H: An imaging target TGF-β1 for hepatocellular carcinoma in
mice. Hell J Nucl Med. 20:76–78. 2017.PubMed/NCBI
|
|
116
|
Balzarini P, Benetti A, Invernici G,
Cristini S, Zicari S, Caruso A, Gatta LB, Berenzi A, Imberti L,
Zanotti C, et al: Transforming growth factor-beta1 induces
microvascular abnormalities through a down-modulation of neural
cell adhesion molecule in human hepatocellular carcinoma. Lab
Invest. 92:1297–1309. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Yao S, Tian C, Ding Y, Ye Q, Gao Y, Yang N
and Li Q: Down-regulation of Krüppel-like factor-4 by
microRNA-135a-5p promotes proliferation and metastasis in
hepatocellular carcinoma by transforming growth factor-β1.
Oncotarget. 7:42566–42578. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Li W, Liu M, Su Y, Zhou X, Liu Y and Zhang
X: The Janus-faced roles of Krüppel-like factor 4 in oral squamous
cell carcinoma cells. Oncotarget. 6:44480–44494. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Tian C, Yao S, Liu L, Ding Y, Ye Q, Dong
X, Gao Y, Yang N and Li Q: Klf4 inhibits tumor growth and
metastasis by targeting microRNA-31 in human hepatocellular
carcinoma. Int J Mol Med. 39:47–56. 2017. View Article : Google Scholar
|
|
120
|
Zhang X, Fan Q, Li Y, Yang Z, Yang L, Zong
Z, Wang B, Meng X, Li Q, Liu J and Li H: Transforming growth
factor-beta1 suppresses hepatocellular carcinoma proliferation via
activation of Hippo signaling. Oncotarget. 8:29785–29794. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Zhang Y, Shi K, Liu H, Chen W, Luo Y, Wei
X and Wu Z: MiR-4458 inhibits the epithelial-mesenchymal transition
of hepatocellular carcinoma cells by suppressing the TGF-β
signaling pathway via targeting TGFBR1. Acta Biochim Biophys Sin
(Shanghai). 52:554–562. 2020. View Article : Google Scholar
|
|
122
|
Perrier ND, Brierley JD and Tuttle RM:
Differentiated and anaplastic thyroid carcinoma: Major changes in
the American Joint Committee on Cancer eighth edition cancer
staging manual. CA Cancer J Clin. 68:55–63. 2018. View Article : Google Scholar
|
|
123
|
Saini S, Tulla K, Maker AV, Burman KD and
Prabhakar BS: Therapeutic advances in anaplastic thyroid cancer: A
current perspective. Mol Cancer. 17:1542018. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Kebebew E: Anaplastic thyroid cancer:
Rare, fatal, and neglected. Surgery. 152:1088–1089. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Li Y, Chen D, Hao FY and Zhang KJ:
Targeting TGF-β1 and AKT signal on growth and metastasis of
anaplastic thyroid cancer cell in vivo. Eur Rev Med Pharmacol Sci.
20:2581–2587. 2016.PubMed/NCBI
|
|
126
|
Zhang X, Liu L, Deng X, Li D, Cai H, Ma Y,
Jia C, Wu B, Fan Y and Lv Z: MicroRNA 483-3p targets Pard3 to
potentiate TGF-β1-induced cell migration, invasion, and
epithelial-mesenchymal transition in anaplastic thyroid cancer
cells. Oncogene. 38:699–715. 2019. View Article : Google Scholar
|
|
127
|
Yin Q, Liu S, Dong A, Mi X, Hao F and
Zhang K: Targeting transforming growth factor-Beta1 (TGF-β1)
inhibits tumorigenesis of anaplastic thyroid carcinoma cells
through ERK1/2-NFκB-PUMA signaling. Med Sci Monit. 22:2267–2277.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Zhong J, Liu C, Zhang QH, Chen L, Shen YY,
Chen YJ, Zeng X, Zu XY and Cao RX: TGF-β1 induces HMGA1 expression:
The role of HMGA1 in thyroid cancer proliferation and invasion. Int
J Oncol. 50:1567–1578. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Cui M, Chang Y, Du W, Liu S, Qi J, Luo R
and Luo S: Upregulation of lncRNA-ATB by transforming growth
factor-β1 (TGF-β1) promotes migration and invasion of papillary
thyroid carcinoma cells. Med Sci Monit. 24:5152–5158. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Li T, Zhao N, Lu J, Zhu Q, Liu X, Hao F
and Jiao X: Epigallocatechin gallate (EGCG) suppresses
epithelial-mesenchymal transition (EMT) and invasion in anaplastic
thyroid carcinoma cells through blocking of TGF-β1/Smad signaling
pathways. Bioengineered. 10:282–291. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
He J, Jin Y, Zhou M, Li X, Chen W, Wang Y,
Gu S, Cao Y, Chu C, Liu X and Zou Q: Solute carrier family 35
member F2 is indispensable for papillary thyroid carcinoma
progression through activation of transforming growth factor-β type
I receptor/apoptosis signal-regulating kinase 1/mitogen-activated
protein kinase signaling axis. Cancer Sci. 109:642–655. 2018.
View Article : Google Scholar :
|
|
132
|
Bonnet D: Cancer stem cells: Lessons from
leukaemia. Cell Prolif. 38:357–361. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Xie W, Wang X, Du W, Liu W, Qin X and
Huang S: Detection of molecular targets on the surface of
CD34+CD38-bone marrow cells in myelodysplastic syndromes. Cytometry
A. 77:840–848. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Lyengar V and Shimanovsky A: Leukemia.
StatPearls Publishing, StatPearls Publishing LLC; Treasure Island,
FL: 2020
|
|
135
|
Hunger SP, Lu X, Devidas M, Camitta BM,
Gaynon PS, Winick NJ, Reaman GH and Carroll WL: Improved survival
for children and adolescents with acute lymphoblastic leukemia
between 1990 and 2005: A report from the children's oncology group.
J Clin Oncol. 30:1663–1669. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Huang F, Wan J, Hu W and Hao S:
Enhancement of anti-leukemia immunity by leukemia-derived exosomes
via downregulation of TGF-β1 expression. Cell Physiol Biochem.
44:240–254. 2017. View Article : Google Scholar
|
|
137
|
Geyh S, Rodríguez-Paredes M, Jäger P, Koch
A, Bormann F, Gutekunst J, Zilkens C, Germing U, Kobbe G, Lyko F,
et al: Transforming growth factor β1-mediated functional inhibition
of mesenchymal stromal cells in myelodysplastic syndromes and acute
myeloid leukemia. Haematologica. 103:1462–1471. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Taetle R, Payne C, Dos Santos B, Russell M
and Segarini P: Effects of transforming growth factor beta 1 on
growth and apoptosis of human acute myelogenous leukemia cells.
Cancer Res. 53:3386–3393. 1993.PubMed/NCBI
|
|
139
|
Verheyden S and Demanet C: NK cell
receptors and their ligands in leukemia. Leukemia. 22:249–257.
2008. View Article : Google Scholar
|
|
140
|
Nursal AF, Pehlivan M, Sahin HH and
Pehlivan S: The Associations of IL-6, IFN-γ, TNF-α, IL-10, and
TGF-β1 functional variants with acute myeloid leukemia in turkish
patients. Genet Test Mol Biomarkers. 20:544–551. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Rouce RH, Shaim H, Sekine T, Weber G,
Ballard B, Ku S, Barese C, Murali V, Wu MF, Liu H, et al: The
TGF-β/SMAD pathway is an important mechanism for NK cell immune
evasion in childhood B-acute lymphoblastic leukemia. Leukemia.
30:800–811. 2016. View Article : Google Scholar
|
|
142
|
Gong Y, Zhao M, Yang W, Gao A, Yin X, Hu
L, Wang X, Xu J, Hao S, Cheng T and Cheng H: Megakaryocyte-derived
excessive transforming growth factor β1 inhibits proliferation of
normal hematopoietic stem cells in acute myeloid leukemia. Exp
Hematol. 60:40–46.e2. 2018. View Article : Google Scholar
|
|
143
|
Wang H, Wu Q, Zhang Y, Zhang HN, Wang YB
and Wang W: TGF-β1-induced epithelial-mesenchymal transition in
lung cancer cells involves upregulation of miR-9 and downregulation
of its target, E-cadherin. Cell Mol Biol Lett. 22:222017.
View Article : Google Scholar
|
|
144
|
Xue C, Hu Z, Jiang W, Zhao Y, Xu F, Huang
Y, Zhao H, Wu J, Zhang Y, Zhao L, et al: National survey of the
medical treatment status for non-small cell lung cancer (NSCLC) in
China. Lung Cancer. 77:371–375. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Yano T, Okamoto T, Fukuyama S and Maehara
Y: Therapeutic strategy for postoperative recurrence in patients
with non-small cell lung cancer. World J Clin Oncol. 5:1048–1054.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Li L, Yan S, Zhang H, Zhang M, Huang G and
Chen M: Interaction of hnRNP K with MAP 1B-LC1 promotes
TGF-β1-mediated epithelial to mesenchymal transition in lung cancer
cells. BMC Cancer. 19:8942019. View Article : Google Scholar
|
|
147
|
Shi S, Zhao J, Wang J, Mi D and Ma Z: HPIP
silencing inhibits TGF-β1-induced EMT in lung cancer cells. Int J
Mol Med. 39:479–483. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Zhang HW, Wang EW, Li LX, Yi SH, Li LC, Xu
FL, Wang DL, Wu YZ and Nian WQ: A regulatory loop involving miR-29c
and Sp1 elevates the TGF-β1 mediated epithelial-to-mesenchymal
transition in lung cancer. Oncotarget. 7:85905–85916. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Jiang W, Xu Z, Yu L, Che J, Zhang J and
Yang J: MicroRNA-144-3p suppressed TGF-β1-induced lung cancer cell
invasion and adhesion by regulating the Src-Akt-Erk pathway. Cell
Biol Int. 2019.Epub ahead of print.
|
|
150
|
Zhao X, Liu Y and Yu S: Long noncoding RNA
AWPPH promotes hepatocellular carcinoma progression through YBX1
and serves as a prognostic biomarker. Biochim Biophys Acta Mol
Basis Dis. 1863:1805–1816. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Zhu F, Zhang X, Yu Q, Han G, Diao F, Wu C
and Zhang Y: LncRNA AWPPH inhibits SMAD4 via EZH2 to regulate
bladder cancer progression. J Cell Biochem. 119:4496–4505. 2018.
View Article : Google Scholar
|
|
152
|
Tang L, Wang T, Zhang Y, Zhang J, Zhao H,
Wang H, Wu Y and Liu K: Long non-coding RNA AWPPH promotes
postoperative distant recurrence in resected non-small cell lung
cancer by upregulating transforming growth factor beta 1 (TGF-β1).
Med Sci Monit. 25:2535–2541. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Chae DK, Park J, Cho M, Ban E, Jang M, Yoo
YS, Kim EE, Baik JH and Song EJ: MiR-195 and miR-497 suppress
tumorigenesis in lung cancer by inhibiting SMURF2-induced TGF-β
receptor I ubiquitination. Mol Oncol. 13:2663–2678. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Hypes MK, Pirisi L and Creek KE:
Mechanisms of decreased expression of transforming growth
factor-beta receptor type I at late stages of HPV16-mediated
transformation. Cancer Lett. 282:177–186. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Xu F, Zhang J, Hu G, Liu L and Liang W:
Hypoxia and TGF-β1 induced PLOD2 expression improve the migration
and invasion of cervical cancer cells by promoting
epithelial-to-mesenchymal transition (EMT) and focal adhesion
formation. Cancer Cell Int. 17:542017. View Article : Google Scholar
|
|
156
|
Li MY, Liu JQ, Chen DP, Li ZY, Qi B, Yin
WJ and He L: p68 prompts the epithelial-mesenchymal transition in
cervical cancer cells by transcriptionally activating the TGF-β1
signaling pathway. Oncol Lett. 15:2111–2116. 2018.PubMed/NCBI
|
|
157
|
Yang L, Yu Y, Xiong Z, Chen H, Tan B and
Hu H: Downregulation of SEMA4C inhibit epithelial-mesenchymal
transition (EMT) and the invasion and metastasis of cervical cancer
cells via inhibiting transforming growth factor-beta 1
(TGF-β1)-induced Hela cells p38 mitogen-activated protein kinase
(MAPK) activation. Med Sci Monit. 26:e9181232020. View Article : Google Scholar
|
|
158
|
Cheng Y, Guo Y, Zhang Y, You K, Li Z and
Geng L: MicroRNA-106b is involved in transforming growth factor
β1-induced cell migration by targeting disabled homolog 2 in
cervical carcinoma. J Exp Clin Cancer Res. 35:112016. View Article : Google Scholar
|
|
159
|
Finkielstein CV and Capelluto DG:
Disabled-2: A modular scaffold protein with multifaceted functions
in signaling. Bioessays. 38(Suppl 1): S45–S55. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Tao MZ, Gao X, Zhou TJ, Guo QX, Zhang Q
and Yang CW: Effects of TGF-beta1 on the proliferation and
apoptosis of human cervical cancer Hela cells in vitro. Cell
Biochem Biophys. 73:737–741. 2015. View Article : Google Scholar
|
|
161
|
Wang H, Wang J, Liu H and Wang X: TGF-β1
activates NOX4/ROS pathway to promote the invasion and migration of
cervical cancer cells. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi.
35:121–127. 2019.In Chinese. PubMed/NCBI
|
|
162
|
Deng M, Cai X, Long L, Xie L, Ma H, Zhou
Y, Liu S and Zeng C: CD36 promotes the epithelial-mesenchymal
transition and metastasis in cervical cancer by interacting with
TGF-β. J Transl Med. 17:3522019. View Article : Google Scholar
|
|
163
|
Wongnoppavich A, Dukaew N, Choonate S and
Chairatvit K: Upregulation of maspin expression in human cervical
carcinoma cells by transforming growth factor β1 through the
convergence of Smad and non-Smad signaling pathways. Oncol Lett.
13:3646–3652. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Ju W, Luo X and Zhang N: LncRNA NEF
inhibits migration and invasion of HPV-negative cervical squamous
cell carcinoma by inhibiting TGF-β pathway. Biosci Rep. Apr
26–2019.Epub ahead of print. View Article : Google Scholar
|
|
165
|
Levovitz C, Chen D, Ivansson E, Gyllensten
U, Finnigan JP, Alshawish S, Zhang W, Schadt EE, Posner MR, Genden
EM, et al: TGFβ receptor 1: An immune susceptibility gene in
HPV-associated cancer. Cancer Res. 74:6833–6844. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Zhu L, Zhang Q, Li S, Jiang S, Cui J and
Dang G: Interference of the long noncoding RNA CDKN2B-AS1
upregulates miR-181a-5p/TGFβI axis to restrain the metastasis and
promote apoptosis and senescence of cervical cancer cells. Cancer
Med. 8:1721–1730. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Wu T, Chen X, Peng R, Liu H, Yin P, Peng
H, Zhou Y, Sun Y, Wen L, Yi H, et al: Let-7a suppresses cell
proliferation via the TGF-β/SMAD signaling pathway in cervical
cancer. Oncol Rep. 36:3275–3282. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Fang F, Huang B, Sun S, Xiao M, Guo J, Yi
X, Cai J and Wang Z: MiR-27a inhibits cervical adenocarcinoma
progression by downregulating the TGF-βRI signaling pathway. Cell
Death Dis. 9:3952018. View Article : Google Scholar
|
|
169
|
Wu M, Chen X, Lou J, Zhang S, Zhang X,
Huang L, Sun R, Huang P, Wang F and Pan S: TGF-β1 contributes to
CD8+ Treg induction through p38 MAPK signaling in ovarian cancer
microenvironment. Oncotarget. 7:44534–44544. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Wang YQ, Li YM, Li X, Liu T, Liu XK, Zhang
JQ, Guo JW, Guo LY and Qiao L: Hypermethylation of TGF-β1 gene
promoter in gastric cancer. World J Gastroenterol. 19:5557–5564.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Ji M, Shi H, Xie Y, Zhao Z, Li S, Chang C,
Cheng X and Li Y: Ubiquitin specific protease 22 promotes cell
proliferation and tumor growth of epithelial ovarian cancer through
synergy with transforming growth factor β1. Oncol Rep. 33:133–140.
2015. View Article : Google Scholar
|
|
172
|
Teng Y, Zhao L, Zhang Y, Chen W and Li X:
Id-1, a protein repressed by miR-29b, facilitates the TGFβ1-induced
epithelial-mesenchymal transition in human ovarian cancer cells.
Cell Physiol Biochem. 33:717–730. 2014. View Article : Google Scholar
|
|
173
|
Facciabene A, Motz GT and Coukos G:
T-regulatory cells: Key players in tumor immune escape and
angiogenesis. Cancer Res. 72:2162–2171. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Zhang J, Liu W, Shen F, Ma X, Liu X, Tian
F, Zeng W, Xi X and Lin Y: The activation of
microRNA-520h-associated TGF-β1/c-Myb/Smad7 axis promotes
epithelial ovarian cancer progression. Cell Death Dis. 9:8842018.
View Article : Google Scholar
|
|
175
|
Wang YQ, Qi XW, Wang F, Jiang J and Guo
QN: Association between TGFBR1 polymorphisms and cancer risk: A
meta-analysis of 35 case-control studies. PLoS One. 7:e428992012.
View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Eli Lilly: Company: A study in
participants with diabetic kidney disease. ClinicalTrials.gov. 2010, https://clinicaltrials.gov/ct2/show/NCT01113801.
Accessed Sep 17, 2019.
|
|
177
|
Zhang Q, Hou X, Evans BJ, VanBlaricom JL,
Weroha SJ and Cliby WA: LY2157299 monohydrate, a TGF-βR1 inhibitor,
suppresses tumor growth and ascites development in ovarian cancer.
Cancers (Basel). 10. pp. 2602018, View Article : Google Scholar
|
|
178
|
Herbertz S, Sawyer JS, Stauber AJ,
Gueorguieva I, Driscoll KE, Estrem ST, Cleverly AL, Desaiah D, Guba
SC, Benhadji KA, et al: Clinical development of galunisertib
(LY2157299 monohydrate), a small molecule inhibitor of transforming
growth factor-beta signaling pathway. Drug Des Devel Ther.
9:4479–4499. 2015.PubMed/NCBI
|
|
179
|
Fujiwara Y, Nokihara H, Yamada Y, Yamamoto
N, Sunami K, Utsumi H, Asou H, TakahashI O, Ogasawara K,
Gueorguieva I and Tamura T: Phase 1 study of galunisertib, a
TGF-beta receptor I kinase inhibitor, in Japanese patients with
advanced solid tumors. Cancer Chemother Pharmacol. 76:1143–1152.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Brandes AA, Carpentier AF, Kesari S,
Sepulveda-Sanchez JM, Wheeler HR, Chinot O, Cher L, Steinbach JP,
Capper D, Specenier P, et al: A Phase II randomized study of
galunisertib monotherapy or galunisertib plus lomustine compared
with lomustine monotherapy in patients with recurrent glioblastoma.
Neuro Oncol. 18:1146–1156. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Ikeda M, Takahashi H, Kondo S, Lahn MMF,
Ogasawara K, Benhadji KA, Fujii H and Ueno H: Phase 1b study of
galunisertib in combination with gemcitabine in Japanese patients
with metastatic or locally advanced pancreatic cancer. Cancer
Chemother Pharmacol. 79:1169–1177. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Rodón J, Carducci M, Sepulveda-Sánchez JM,
Azaro A, Calvo E, Seoane J, Braña I, Sicart E, Gueorguieva I,
Cleverly A, et al: Pharmacokinetic, pharmacodynamic and biomarker
evaluation of transforming growth factor-β receptor I kinase
inhibitor, galunisertib, in phase 1 study in patients with advanced
cancer. Invest New Drugs. 33:357–370. 2015. View Article : Google Scholar
|
|
183
|
MedPacto: Dose escalation and
proof-of-concept studies of vactosertib (TEW-7197) monotherapy in
patients with MDS. ClinicalTrials.gov. 2017,
https://clinicaltrials.gov/ct2/show/NCT03074006.
Accessed Mar 24, 2020.
|
|
184
|
MedPacto: First in human dose escalation
study of vactosertib (TEW-7197) in subjects with advanced stage
solid tumors. ClinicalTrials.gov. 2014, https://clinicaltrials.gov/ct2/show/NCT02160106
Accessed Sep 5, 2019.
|
|
185
|
Eli Lilly: Company: A study of LY3200882
in participants with solid tumors. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/results/NCT02937272.
Accessed Aug 19, 2020.
|
|
186
|
Callahan JF, Burgess JL, Fornwald JA,
Gaster LM, Harling JD, Harrington FP, Heer J, Kwon C, Lehr R,
Mathur A, et al: Identification of novel inhibitors of the
transforming growth factor beta1 (TGF-beta1) type 1 receptor
(ALK5). J Med Chem. 45:999–1001. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Inman GJ, Nicolás FJ, Callahan JF, Harling
JD, Gaster LM, Reith AD, Laping NJ and Hill CS: SB-431542 is a
potent and specific inhibitor of transforming growth factor-beta
super-family type I activin receptor-like kinase (ALK) receptors
ALK4, ALK5, and ALK7. Mol Pharmacol. 62:65–74. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Tanaka H, Shinto O, Yashiro M, Yamazoe S,
Iwauchi T, Muguruma K, Kubo N, Ohira M and Hirakawa K: Transforming
growth factor β signaling inhibitor, SB-431542, induces maturation
of dendritic cells and enhances anti-tumor activity. Oncol Rep.
24:1637–1643. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Melisi D, Ishiyama S, Sclabas GM, Fleming
JB, Xia Q, Tortora G, Abbruzzese JL and Chiao PJ: LY2109761, a
novel transforming growth factor beta receptor type I and type II
dual inhibitor, as a therapeutic approach to suppressing pancreatic
cancer metastasis. Mol Cancer Ther. 7:829–840. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Zhang ZH, Miao YY, Ke BL, Liu K and Xu X:
LY2109761, transforming growth factor β receptor type I and type II
dual inhibitor, is a novel approach to suppress endothelial
mesenchymal transformation in human corneal endothelial cells. Cell
Physiol Biochem. 50:963–972. 2018. View Article : Google Scholar
|
|
191
|
Tandon M, Salamoun JM, Carder EJ, Farber
E, Xu S, Deng F, Tang H, Wipf P and Wang QJ: SD-208, a novel
protein kinase D inhibitor, blocks prostate cancer cell
proliferation and tumor growth in vivo by inducing G2/M cell cycle
arrest. PLoS One. 10:e01193462015. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Araujo SC, Maltarollo VG, Almeida MO,
Ferreira LL, Andricopulo AD and Honorio KM: Structure-based virtual
screening, molecular dynamics and binding free energy calculations
of Hit candidates as ALK-5 inhibitors. Molecules. 25:2642020.
View Article : Google Scholar :
|
|
193
|
de Gouville AC, Boullay V, Krysa G, Pilot
J, Brusq JM, Loriolle F, Gauthier JM, Papworth SA, Laroze A,
Gellibert F and Huet S: Inhibition of TGF-beta signaling by an ALK5
inhibitor protects rats from dimethylnitrosamine-induced liver
fibrosis. Br J Pharmacol. 145:166–177. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Park CY, Kim DK and Sheen YY: EW-7203, a
novel small molecule inhibitor of transforming growth factor-β
(TGF-β) type I receptor/activin receptor-like kinase-5, blocks
TGF-β1-mediated epithelial-to-mesenchymal transition in mammary
epithelial cells. Cancer Sci. 102:1889–1896. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Ehata S, Hanyu A, Fujime M, Katsuno Y,
Fukunaga E, Goto K, Ishikawa Y, Nomura K, Yokoo H, Shimizu T, et
al: Ki26894, a novel transforming growth factor-beta type I
receptor kinase inhibitor, inhibits in vitro invasion and in vivo
bone metastasis of a human breast cancer cell line. Cancer Sci.
98:127–133. 2007. View Article : Google Scholar
|
|
196
|
Suzuki E, Kim S, Cheung HK, Corbley MJ,
Zhang X, Sun L, Shan F, Singh J, Lee WC, Albelda SM and Ling LE: A
novel small-molecule inhibitor of transforming growth factor beta
type I receptor kinase (SM16) inhibits murine mesothelioma tumor
growth in vivo and prevents tumor recurrence after surgical
resection. Cancer Res. 67:2351–2359. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Moore-Smith LD, Isayeva T, Lee JH, Frost A
and Ponnazhagan S: Silencing of TGF-β1 in tumor cells impacts MMP-9
in tumor microenvironment. Sci Rep. 7:86782017. View Article : Google Scholar
|
|
198
|
Li XF, Yan PJ and Shao ZM: Downregulation
of miR-193b contributes to enhance urokinase-type plasminogen
activator (uPA) expression and tumor progression and invasion in
human breast cancer. Oncogene. 28:3937–3948. 2009. View Article : Google Scholar : PubMed/NCBI
|
